Peetz joins Frazier Life Sciences team

Frazier Healthcare Partners said May 30 that Chris Peetz has joined the Life Sciences team as an Entrepreneur-in-Residence. Peetz most recently served as CFO and head of corporate development at Frazier portfolio company Tobira Therapeutics.

PRESS RELEASE

MENLO PARK, Calif.–(BUSINESS WIRE)–Frazier Healthcare Partners announced today that Chris Peetz has joined the Life Sciences team as an Entrepreneur-in-Residence (EIR). Most recently, Mr. Peetz served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics to treat non-alcoholic steatohepatitis (NASH). While at Tobira, Mr. Peetz led the company’s efforts to become a public company through a reverse merger, expand its pipeline through partnerships and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Mr. Peetz held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.

As an EIR with Frazier, Mr. Peetz will focus on identifying and in-licensing assets into a newly formed search company, Flashlight Therapeutics. Mr. Peetz serves as the CEO of Flashlight, which is broadly focused on oncology, liver diseases and NASH, and related areas.
“Chris played an instrumental role in the success of Tobira, and he brings unique partnering and financing insights to our team having been involved in growing companies resulting in over $15 billion in corporate transactions,” said Patrick Heron, Managing General Partner with the Frazier Life Sciences team. “He has deep experience in areas ranging from oncolytic viruses to the leading edge of NASH combination therapies, and we look forward to working with him to build a new company around in-licensed assets.”
About Frazier Healthcare Partners
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $3.0 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.
For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.
About Flashlight Therapeutics
Headquartered in Menlo Park, Calif., Flashlight Therapeutics is a Frazier-founded search company focused on in-licensing and developing therapeutics.